Whole genome sequence-based haplotypes reveal a single origin of the 1393 bp HBB deletion

Germline mutations of HBB gene that reduces its expression give rise to b thalassemia, and nearly 300 of these have been described. Deletions causing b-thalassemia are very rare. We have identified three individuals with identical HBB deletions of 1,393 bp associated with relatively high levels of hemoglobin A2 and hemoglobin. Using information from whole genome […]

Read More…

Xq28 copy number gain causing moyamoya disease and a novel moyamoya syndrome

Moyamoya angiopathy is a rare cerebrovascular disorder. Its main clinical manifestations include ischemic and hemorrhagic stroke. A few genes and cytogenetic anomalies have been reported in a limited number of patients. However, the molecular causative anomaly is so far unknown in most moyamoya patients. In this study, we identified a novel association between an Xq28 […]

Read More…

FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heart muscle disease that affects predominantly the right ventricle and cause sudden cardiac death. We studied 156 ARVC patients lacking variants in known ARVC genes, and identified two unique FLNCtv variants in two families fulfilling “definite” diagnosis according to the 2010 ARVC Task Force Criteria. Segregation analysis revealed […]

Read More…

Increased TBX6 Gene Dosages Induce Congenital Cervical Vertebral Malformations in Humans and Mice

We previously reported that the human 16p11.2 BP4-BP5 deletion and its associated TBX6 dosage reduction caused congenital vertebral malformations (CVMs) in thoracic and lumber vertebrae. Here we reveal genetic contributions of the reciprocal 16p11.2 BP4-BP5 duplication to cervical CVMs. The spinal assessments in seven duplication carriers showed that four presented characteristics of cervical CVMs. We […]

Read More…

Gene editing prospects for treating inherited retinal diseases

Retinal diseases can result from genetic mutations or combined risk factors, all causing vision impairment progressing to blindness. To date, available therapeutic approaches result in inefficient and expensive treatments. The CRISPR-Cas9 system, an RNA-guided genome editing technology, may be applied to precisely correct or remove disease-related genetic mutations, or induce permanent inhibition of factors promoting […]

Read More…

Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease

All clinical trials for drugs aimed to stop diseases such as Parkinson’s disease and Alzheimer’s disease have failed, and currently there are no drugs that can stop or slow down these diseases. In parallel, we have gathered a lot of data on how genetics affect the risk for these diseases and their clinical progression. However, […]

Read More…

Cardiac valve involvement in ADAR-related type I interferonopathy

The contribution of inflammation to inherited neurological diseases is not well understood. One subgroup of neurological diseases is caused by abnormalities of chemicals known as Type I interferons. We report for the first time heart valve calcification in three children that occurred as a complication of Type I interferon-associated neurodisability caused by mutations in the […]

Read More…

Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY)

People who are born with a pathogenic (disease-causing) variant in the TP53 gene have a very high lifetime risk of developing cancer – almost 100% for women and 75% for men.  The SIGNIFY study, which reported last year, found that whole body Magnetic Resonance Imaging (WB-MRI) in people known to carry a pathogenic variant in […]

Read More…